NCT06781034|Recruiting
Descriptive Study on MRI Contrast of Acute Cerebral Hemorrhage in Different Microangiopathies
GADO-ICH
Loading search results
GADO-ICH
Sponsor study identifier
observational
128
1 country
1
Study Start
February 3, 2025
Actual (reported)Primary Completion
December 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Cerebral haemorrhage represents a minority of acute vascular syndromes (less frequent than ischemic stroke, at around 20%), but with a therapeutic impasse, having no specific treatment. Arterial contrast ("spot sign") within the hematoma has been described in CT scans as a risk factor for further enlargement and poor prognosis. An equivalent marker has also been described in gadolinium-enhanced MRI. By studying the radiological appearance of gadolinium "spot signs" on MRI, which has better parenchymal resolution, the researchers propose to retrace the phenomenology of the acute phase of cerebral hemorrhage in order to better estimate the risk of radiological aggravation by subgroup, which could serve as a target population for future therapeutic trials.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 13, 2025
Actual (reported)January 17, 2025
Actual (reported)February 3, 2025
Actual (reported)December 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
December 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Presence of spot sign on gadolinium MRI
Presence of spot sign on gadolinium MRI (Yes/No)
baseline
Morphologic description of gadolinium MRI spot sign
morphological (shape, location within the hematoma) description of spot signs on brain MRI
baseline
Quantitative description of gadolinium MRI spot sign
Quantitative (number and categorial) description of spot signs on brain MRI
baseline
association of spot sign with hematoma expansion on follow-up CT
Baseline
Association with the underlaying pathology
Baseline
None, pure observational study
None, pure observational study
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Patients with acute cerebral hematoma from existing databases of cerebral amyloid angiopathy and hypertensive microangiopathy; who underwent a follow-up cerebral CT scan in the event of worsening or for follow-up.
CHU de Nîmes
Nîmes, Gard, 30029, France
Anissa MEGZARI
Centre Hospitalier Universitaire de Nīmes
First Submitted
January 13, 2025
First Posted
January 17, 2025
Study Start
February 3, 2025
Actual (reported)Primary Completion
December 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Role of Neuroinflammation and Blood-Brain Barrier Breakdown in Intracerebral Hemorrhage.
Contact the study team to confirm eligibility.
Study Completion
December 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
July 1, 2026
Record last verified: 2026-06
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: